Inactivating mutations in Notch pathway components, particularly in the NOTCH1 and NOTCH2 receptor and RBPJ genes, have been detected in isocitrate dehydrogenase (IDH) mutant gliomas [21,23,26,27,29,32]. This evidence concerns the gene RBPJ and central nervous system cancer.